Table 1 Characteristics of the study population
Non-survivors | Survivors | |||
|---|---|---|---|---|
Variable | Mean/Median | SEM/IQR/% | Mean/Median | SEM/IQR/% |
Women (n/%) | 36 | 73.5 | 70 | 68.6 |
Age (months) | 1079.7 | 0.52 | 1079.9 | 0.32 |
Systolic blood pressure (mmHg) | 141 | 3.75 | 150 | 2.92 |
Diastolic blood pressure (mmHg)* | 70.5 | 14.5 | 74.5 | 19.0 |
Weight (kg) | 63.3 | 1.96 | 70.0 | 1.32 |
BMI (kg/m2) | 24.8 | 0.67 | 27.1 | 0.46 |
Waist circumference (cm) | 89.4 | 1.93 | 94.0 | 1.25 |
Hip circumference (cm)* | 98.5 | 11.0 | 102 | 11.5 |
MMSE* | 24.0 | 7.0 | 26.0 | 4.0 |
Barthel index* | 95.0 | 20.0 | 97.5 | 5.0 |
Handgrip (kg)* | 18.0 | 10.5 | 20.0 | 6.5 |
Able to perform chair-rise test (n = yes/%) | 29 | 63.0 | 82 | 80.4 |
Able to perform chair-stand test (n = yes/%) | 32 | 72.7 | 87 | 86.1 |
Frailty index (n/%) | ||||
Non-frail | 3 | 6.1 | 35 | 34.3 |
Pre-frail | 32 | 65.3 | 52 | 51.0 |
Frail | 14 | 28.6 | 15 | 14.7 |
CRP level (ng/ml)* | 2.2 | 7.5 | 2.0 | 3.2 |
IL-1β level (pg/ml)* | 14.4 | 27.4 | 20.9 | 33.5 |
IL-6 level (pg/ml)* | 4.9 | 3.1 | 3.8 | 3.9 |
IL-7 level (pg/ml)* | 8.0 | 4.5 | 7.5 | 5.4 |
IL-10 level (pg/ml)* | 1.56 | 1.23 | 1.52 | 1.62 |
cf-DNA level (μg/ml)* | 0.92 | 0.21 | 0.87 | 0.17 |
Unmethylated cf-DNA level (μg/ml)* | 0.73 | 0.20 | 0.67 | 0.16 |
Plasma mtDNA (copy number)* | 4.27E8 | 2.68E8 | 3.64E8 | 2.32E8 |
Alu repeat cf-DNA (GE)* | 80.2 | 62.7 | 66.5 | 38.3 |
DHEAS (μg/ml)* | 0.25 | 0.48 | 0.24 | 0.29 |
Cortisol (ng/ml)* | 133 | 55.9 | 125 | 60.9 |
IDO activity (Kyn/Trp)* | 52.7 | 23.3 | 50.8 | 23.2 |
Anti-CMV antibody titer | 19200 | 1145 | 19141 | 830 |
Anti-EBV antibody titer* | 410 | 310 | 385 | 380 |
CD3+ cells (%)*a | 60.9 | 21.5 | 57.0 | 13.8 |
CD4+ cells (%)b | 62.3 | 2.38 | 63.6 | 1.42 |
CD8+ cells (%)b | 31.0 | 2.21 | 29.2 | 1.33 |
CD4+/CD8+ cells (ratio)* | 2.29 | 2.40 | 2.29 | 2.38 |
CD4+CD28- cells (%)*c | 11.0 | 17.0 | 10.0 | 12.0 |
CD8+CD28- cells (%)*d | 65.2 | 29.4 | 69.1 | 23.7 |
CD14+ cells (%)*a | 9.5 | 8.6 | 9.5 | 6.4 |